Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Zilretta Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentHealthSpringPolicy RX501.196

    Triamcinolone Acetonide Extended-Release Injectable Suspension (Zilretta)

    Customize your policy alerts

    Sign up for healthspring Policy RX501.196 alerts

    Get alerted when Policy RX501.196 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and medical-necessity criteria for Zilretta, an extended-release intra-articular triamcinolone acetonide injection, for HealthSpring members. It covers FDA-approved use for knee osteoarthritis when specified clinical criteria are met and identifies other uses as experimental, investigational, or unproven.

    Policy Summary
    PayerHealthSpring
    PolicyTriamcinolone Acetonide Extended-Release Injectable Suspension (Zilretta)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 15, 2026
    Next Review DateN/A
    Key ActionDocument radiologic evidence confirming knee osteoarthritis and at least one prior intra-articular corticosteroid injection before Zilretta treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Knee OACovered indication
    3Required criteria
    32 mg/5 mLSingle dose
    Intra-articularPermitted route

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Unproven
    Repeat administration

    Coverage Criteria

    Knee osteoarthritis

    May be considered medically necessary when ALL of the following are met:

    Knee osteoarthritis coverage criteria

    • Radiologic confirmation: Radiologic evidence confirms osteoarthritis of the knee.
    • Prior intra-articular corticosteroid injection: The individual has tried at least one intra-articular corticosteroid injection in the knee to be treated.At least 1 prior injection
    • No retreatment of previously treated knee: The individual is not receiving retreatment of a knee previously treated with Zilretta.No prior Zilretta treatment in the requested knee

    Experimental, investigational, or unproven uses

    Considered experimental, investigational, and/or unproven for all other non-FDA-approved indications, including but not limited to:

    Unproven uses and routes

    • Small-joint injection: Injection in small joints such as the hand.
    • Shoulder or hip osteoarthritis: Management of osteoarthritis of the shoulder or hip, for which efficacy and safety have not been evaluated.
    • Non-intra-articular administration: Administration by the epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous route.

      Zilretta is for intra-articular use only.

    • Repeat administration of Zilretta, because efficacy and safety have not been demonstrated.

    Initial Zilretta therapy for knee osteoarthritis

    Covered when all of the following are met.

    Covered knee osteoarthritis treatment

    • Radiologic confirmation: Radiologic evidence confirms the individual has osteoarthritis of the knee.
    • Prior corticosteroid treatment: The individual has tried at least one intraarticular corticosteroid injection in the knee to be treated.At least 1 prior intraarticular corticosteroid injection
    • No retreatment of previously treated knee: The individual is not receiving retreatment of a knee previously treated with Zilretta.No retreatment of a previously treated knee

    Zilretta may be considered medically necessary for knee osteoarthritis when radiologic evidence confirms osteoarthritis, the individual has tried at least one intra-articular corticosteroid injection in the knee to be treated, and the requested knee has not previously been treated with Zilretta. Other uses are considered experimental, investigational, and/or unproven, including injections in small joints such as the hand, treatment of shoulder or hip osteoarthritis, administration by non-intra-articular routes, and repeat administration.

    Injection of Zilretta into small joints such as the hand is considered experimental, investigational, and/or unproven and is not covered.

    Use of Zilretta for osteoarthritis of the shoulder or hip is considered experimental, investigational, and/or unproven because efficacy and safety have not been evaluated.

    Administration of Zilretta by an epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous route is considered experimental, investigational, and/or unproven. Zilretta is for intra-articular use only.

    Repeat administration of Zilretta is considered experimental, investigational, and/or unproven because efficacy and safety have not been demonstrated.

    Billing and Coding

    HCPCS CodesHCPCS
    J3304HCPCS code listed for Zilretta

    Provider Requirements and Coverage Risks

    Step Therapy

    Prior Intra-articular Corticosteroid Trial Required

    Before requesting Zilretta, document that the member has tried at least one prior intra-articular corticosteroid injection in the knee to be treated.

    • At least one prior knee injection is required.
    • The prior injection must be in the same knee for which Zilretta is requested.
    Documentation Required

    Radiologic Confirmation Required

    Submit imaging documentation confirming osteoarthritis of the knee to be treated.

    • Radiologic evidence must support the knee osteoarthritis diagnosis.
    Documentation Required

    Clinical Background

    Zilretta is an extended-release formulation of triamcinolone acetonide administered by intra-articular injection for osteoarthritis pain of the knee. The prescribing information specifies a single 32 mg/5 mL intra-articular injection; Zilretta is for intra-articular use only.

    Definitions

    Zilretta
    FormulationExtended-release intra-articular suspension of triamcinolone acetonide
    AdministrationAdministered as a single intra-articular injection
    Dose32 mg in 5 mL
    Intra-articular use
    DefinitionAdministration directly into a joint
    Permitted routeIntra-articular use only
    Other routesNot administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes

    Initial Therapy Criteria

    Initial knee osteoarthritis treatment

    Initial treatment may be considered medically necessary when ALL of the following are met:

    Initial Zilretta treatment

    • Radiologic evidence confirms osteoarthritis of the knee.
    • Prior corticosteroid trial: The individual has tried at least one intra-articular corticosteroid injection in the knee to be treated.At least 1 injection
    • No previous Zilretta in requested knee: The individual is not receiving retreatment of a knee previously treated with Zilretta.No prior treatment of requested knee

    Step Therapy Requirement

    StepRequirement
    1Try at least one intra-articular corticosteroid injection in the knee to be treated before Zilretta.
    StepRequirement
    1Try at least one intraarticular corticosteroid injection in the knee to be treated before Zilretta.

    Quantity and Dose Limits

    Quantity limit
    ProductZilretta extended-release intra-articular injection
    Quantity limitSingle 32 mg (5 mL) injection per course
    RouteIntra-articular use only
    Policy Summary
    PayerHealthSpring
    PolicyTriamcinolone Acetonide Extended-Release Injectable Suspension (Zilretta)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 15, 2026
    Next Review DateN/A
    Key ActionDocument radiologic evidence confirming knee osteoarthritis and at least one prior intra-articular corticosteroid injection before Zilretta treatment.
    SourceLink
    On This Page
    Coverage CriteriaBilling and CodingProvider Requirements and Coverage RisksClinical BackgroundDefinitionsInitial Therapy CriteriaStep Therapy RequirementQuantity and Dose Limits

    Prior Knee Injection Documentation

    Document at least one prior intra-articular corticosteroid injection in the knee for which Zilretta is requested.

    • Identify the treated knee and the prior injection history in the clinical record.
    Denial Risk

    No Prior Zilretta Treatment

    Confirm that the requested knee has not previously been treated with Zilretta. Re-treatment of a previously treated knee is not covered under the medical-necessity criteria.

    • Document the absence of prior Zilretta treatment for the requested knee.
    Billing Rule

    Review Member Benefit Documents

    Coverage determinations must be made together with review of the member’s benefit contract or Summary Plan Description (SPD).

    • Check defined coverage and non-coverage provisions.
    • Check benefit exclusions and limitations, including dollar or duration caps.
    Documentation Required

    Required Clinical Documentation

    Include a complete clinical documentation packet with the request, consolidating the radiologic confirmation of knee osteoarthritis and evidence of at least one prior intra-articular corticosteroid injection in the knee to be treated.

    • Include the relevant imaging report or equivalent radiologic evidence.
    • Include documentation of the prior knee injection.
    Denial Risk

    Required Coverage Criteria Not Met

    A request may be denied when any required coverage criterion is missing or not met, including the required imaging, prior knee corticosteroid injection, or confirmation that the knee has not previously received Zilretta.

    • All medical-necessity criteria must be documented.
    • Review the member’s benefit documents for additional coverage requirements or limitations.
    Denial Risk

    Unapproved Use or Administration Route

    Zilretta is covered only for its FDA-approved use and intra-articular administration. Requests for non-approved indications or administration by a non-approved route are experimental, investigational, and/or unproven.

    • Zilretta is administered as a single intra-articular extended-release injection delivering 32 mg in 5 mL.
    • Do not request administration for non-approved indications or routes.
    Billing Rule

    Do Not Substitute Formulations

    Do not substitute Zilretta for another injectable triamcinolone acetonide formulation. Zilretta is not substitutable with other formulations of injectable triamcinolone acetonide.

    • Use the specifically prescribed Zilretta formulation.
    Denial Risk

    Failure to Meet Knee Osteoarthritis Criteria

    Knee treatment requests that do not meet the radiologic osteoarthritis, prior intra-articular corticosteroid injection, and no-prior-Zilretta-treatment criteria may be denied.

    • The criteria apply to the specific knee being treated.
    • Document all criteria before submission.
    Denial Risk

    Non-approved Indications

    Zilretta is experimental, investigational, and/or unproven for all other non-FDA-approved indications, including injection in small joints such as the hand and treatment of osteoarthritis pain of the shoulder or hip.

    • Efficacy and safety for shoulder and hip osteoarthritis have not been evaluated.
    • Zilretta is not suitable for use in small joints such as the hand.
    Denial Risk

    Non-covered Administration Routes

    Zilretta is for intra-articular use only. Administration by any of the routes listed below is not covered and may result in denial.

    • Do not administer epidurally, intrathecally, intravenously, intraocularly, intramuscularly, intradermally, or subcutaneously.
    Denial Risk

    Repeat Administration Not Covered

    Repeat administration of Zilretta is experimental, investigational, and/or unproven because efficacy and safety of repeat administration have not been demonstrated.

    • Zilretta is intended as a single intra-articular extended-release injection.
    • Do not request re-treatment of a knee previously treated with Zilretta.
    Osteoarthritis
    DefinitionThe most common form of arthritis and a degenerative joint condition
    Joint pathologyInvolves cartilage degradation, bone remodeling, osteophyte formation, and synovial inflammation
    EffectsMay cause pain, stiffness, swelling, and loss of normal joint function
    Intra-articular injection
    DefinitionInjection of medication directly into a joint
    Role in knee osteoarthritisAn intra-articular corticosteroid injection is one treatment option for knee osteoarthritis pain
    Clinical useIntra-articular corticosteroid injections are often conditionally advised in knee osteoarthritis over other intra-articular injections

    Initial therapy

    Initial Zilretta treatment may be considered medically necessary when all of the following are met.

    Initial therapy criteria

    • Radiologic evidence confirms osteoarthritis of the knee.
    • Prior intraarticular corticosteroid injection: The individual has tried at least one intraarticular corticosteroid injection in the knee to be treated.At least 1 injection
    • No prior Zilretta treatment in the knee: The individual is not receiving retreatment of a knee previously treated with Zilretta.No retreatment